Document is current
Any future updates will be listed below
-
Authors
van Dijk, Nick
Gil-Jimenez, Alberto https://orcid.org/0000-0003-0643-6676
Silina, Karina https://orcid.org/0000-0003-3947-2710
Hendricksen, Kees
Smit, Laura A.
de Feijter, Jeantine M.
van Montfoort, Maurits L.
van Rooijen, Charlotte
Peters, Dennis
Broeks, Annegien
van der Poel, Henk G.
Bruining, Annemarie
Lubeck, Yoni
Sikorska, Karolina
Boellaard, Thierry N.
Kvistborg, Pia
Vis, Daniel J.
Hooijberg, Erik https://orcid.org/0000-0002-4482-2191
Schumacher, Ton N. https://orcid.org/0000-0003-0517-8804
van den Broek, Maries https://orcid.org/0000-0002-9489-3692
Wessels, Lodewyk F. A. https://orcid.org/0000-0002-1656-6995
Blank, Christian U. https://orcid.org/0000-0002-7945-5846
van Rhijn, Bas W.
van der Heijden, Michiel S. https://orcid.org/0000-0002-4407-7881
- License Information
-
More Information
Article History
Received: 11 April 2020
Accepted: 28 August 2020
First Online: 12 October 2020
Competing interests
: T.N.S. is a consultant for Adaptive Biotechnologies, AIMM Therapeutics, Allogene Therapeutics, Amgen, Merus, Neon Therapeutics and Scenic Biotech. T.N.S. has received grant and research support from Merck, Bristol-Myers Squibb and Merck KGaA. T.N.S. is a stockholder in AIMM Therapeutics, Allogene Therapeutics and Neon Therapeutics. L.F.A.W. reports research funding from Genmab. C.U.B. reports personal fees for advisory roles for Merck Sharp & Dohme, Bristol-Myers Squibb, Roche, GlaxoSmithKline, Novartis, Pfizer, Genmab and Eli Lilly and grants from Bristol-Myers Squibb, NanoString and Novartis. M.S.v.d.H. has received research support from Bristol-Myers Squibb, AstraZeneca and Roche and consultancy fees from Bristol-Myers Squibb, Merck, Merck Sharp & Dohme, Roche, AstraZeneca, Seattle Genetics and Janssen (all paid to the Netherlands Cancer Institute). No other authors have disclosures relevant to this work.
